Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Hepatology Research2018Vol. 49(1), pp. 111–117
Citations Over TimeTop 10% of 2018 papers
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Koichi Takaguchi, Ei Itobayashi, Noritomo Shimada, Kazuto Tajiri, Kunihiko Tsuji, Toru Ishikawa, Hironori Ochi, Masashi Hirooka, Akemi Tsutsui, Hiroshi Shibata, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka
Abstract
Early therapeutic response to LEN was favorable. This new TKI could have therapeutic potential both in patients with and without past TKI treatments.
Related Papers
- → Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial(2018)350 cited
- → Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment(2017)66 cited
- → Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging(2019)24 cited
- → Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting(2021)7 cited
- → P-40 Lenvatinib versus sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study(2021)